SCHEMBL4921029

SCHEMBL4921029

CCOC(=O)c1ccc(NC(=O)Nc2ncc(C(=O)OCC)c(C)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.61
▸ NPC1 O15118 5/20 0.61
▸ MEN1 O00255 4/20 0.57
▸ KMT2A Q03164 4/20 0.57
▸ TRPV1 Q8NER1 2/20 0.57
▸ CASP3 P42574 1/20 0.57
▸ SENP7 Q9BQF6 1/20 0.57
▸ RAB9A P51151 5/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56
▸ POLB P06746 1/20 0.55
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ CA12 O43570 1/20 0.54
▸ CA1 P00915 1/20 0.54
▸ CA2 P00918 1/20 0.54
▸ CA9 Q16790 1/20 0.54
▸ GAA P10253 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ NAMPT P43490 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5175760 0.93 MAPT (0.56) MAPTNPC1MEN1KMT2ATRPV1
SCHEMBL8398108 0.78 RAB9A (0.64) MAPTNPC1MEN1KMT2ARAB9A
SCHEMBL19453365 0.76 RAB9A (0.65) MAPTNPC1MEN1KMT2ARAB9A
SCHEMBL4919298 0.76 RAB9A (0.73) MAPTNPC1MEN1KMT2ATRPV1
SCHEMBL4113307 0.76 MAPT (0.77) MAPTNPC1MEN1KMT2ATRPV1
SCHEMBL4595936 0.76 MAPT (0.78) MAPTNPC1MEN1KMT2ARAB9A
SCHEMBL4112717 0.75 MAPT (0.76) MAPTNPC1MEN1KMT2ATRPV1
SCHEMBL4107238 0.75 KMT2A (0.67) MAPTNPC1MEN1KMT2ATRPV1
SCHEMBL4597201 0.75 MAPT (0.69) MAPTNPC1MEN1KMT2ARAB9A
SCHEMBL4915127 0.75 MAPT (0.75) MAPTNPC1MEN1KMT2ATRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 — — US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 — — US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 — — US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 — — US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 — — US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 — — US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 — — US disclosed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 — — EP disclosed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MAPT 4151/4885NPC1 148/4885MEN1 4843/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MAPT 4151/4885NPC1 148/4885MEN1 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback